OrbiMed’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

OrbiMed’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-116,594	Closed	-$3.16M	–	149
2014 Q2	$3.16M	Hold	116,594	–	–	0.04%	122
2014 Q1	$3.13M	Hold	116,594	–	–	0.04%	128
2013 Q4	$2.86M	Hold	116,594	–	–	0.04%	108
2013 Q3	$3.75M	Hold	116,594	–	–	0.07%	109
2013 Q2	$3.43M	Buy	+116,594	New	+$4.35M	0.07%	113

Other funds holding ANTH

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

OrbiMed's ANTH Position: Q3 2014 in Review

OrbiMed sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2014, closing a stake of 116,594 shares — an estimated $3.16M sold.

OrbiMed first reported a position in ANTH in Q2 2013 and held it in 5 quarters. The position peaked at $3.75M in Q3 2013. 35 funds tracked by Wall St. Rank hold ANTH as of Q3 2014.

OrbiMed reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
OrbiMed sold 116,594 Anthera Pharmaceuticals, Inc. shares in Q3 2014, an estimated $3.16M.
OrbiMed first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
OrbiMed's Anthera Pharmaceuticals, Inc. position peaked at $3.75M in Q3 2013.
35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2014.

Based on OrbiMed's 13F filing for Q3 2014, filed 14 Nov 2014.